Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | Director | July 01, 2020 | July 06, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IONIS PHARMACEUTICALS INC
Report date July 01, 2020 · Filed July 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,183 |
Ending reported balance
After 2020-07-06 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2020-07-01 · Exercise / conversion · Acquired 666 · Balance 15,849 F1: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Row 2 · 2020-07-01 · Exercise / conversion · Acquired 1,778 · Balance 17,627 F1: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Row 3 · 2020-07-02 · Exercise / conversion · Acquired 889 · Balance 18,516 F1: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Row 4 · 2020-07-06 · Exercise / conversion · Acquired 667 · Balance 19,183 F1: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-07-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-07-01 · Exercise / conversion · Disposed 666 · Balance 0 F2: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,332 |
Reported balance
After 2020-07-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-07-01 · Exercise / conversion · Disposed 1,778 · Balance 5,332 F2: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,777 |
Reported balance
After 2020-07-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-07-02 · Exercise / conversion · Disposed 889 · Balance 1,777 F2: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 666 |
Reported balance
After 2020-07-06 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-07-06 · Exercise / conversion · Disposed 667 · Balance 666 F2: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 5,333 |
Reported balance
After 2020-07-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-07-01 · Grant · Acquired 5,333 · Balance 5,333 F2: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4: Grant of July 1, 2020 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2020. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.20 · Expires 2030-06-30 | Direct | 12,000 |
Reported balance
After 2020-07-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-07-01 · Grant · Acquired 12,000 · Balance 12,000 F5: Grant of July 1, 2020 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.
F2: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
F3: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.
F4: Grant of July 1, 2020 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2020.
F5: Grant of July 1, 2020 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2020.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
USMD Holdings, Inc.
Report date September 30, 2016 · Filed October 04, 2016
Section 16 reporting ended · disclosed 2016-10-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock ($.01 par value)SEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-09-30 transaction · row 1
1 source rowRow 1 · 2016-09-30 · Disposition to issuer · Disposed 14,491 · Balance 0 F1: Disposed of at the effective time of the merger of Project Z Merger Sub, Inc. ("Merger Sub"), a wholly-owned subsidiary of WellMed Medical Management, Inc., a Texas corporation ("WellMed"), with and into the issuer (the "Merger"), pursuant to that certain Agreement and Plan of Merger dated August 29, 2016, between the issuer, WellMed and Merger Sub, in exchange for a cash payment of $22.34 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of at the effective time of the merger of Project Z Merger Sub, Inc. ("Merger Sub"), a wholly-owned subsidiary of WellMed Medical Management, Inc., a Texas corporation ("WellMed"), with and into the issuer (the "Merger"), pursuant to that certain Agreement and Plan of Merger dated August 29, 2016, between the issuer, WellMed and Merger Sub, in exchange for a cash payment of $22.34 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2020 Filed Jul 6, 2020 21:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 667 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000096 · edgar.xml · derivative · entry 8 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666 Underlying: Common Stock · 667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 06, 2020 Filed Jul 6, 2020 21:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 667 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000096 · edgar.xml · nonDerivative · entry 4 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| July 02, 2020 Filed Jul 6, 2020 21:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 889 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000096 · edgar.xml · derivative · entry 7 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,777 Underlying: Common Stock · 889 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 02, 2020 Filed Jul 6, 2020 21:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 889 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000096 · edgar.xml · nonDerivative · entry 3 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantDirector Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $60.20 | $0.00 |
DisclosureSEC source: 0000874015-20-000096 · edgar.xml · derivative · entry 10 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-30 F5 · derivative.exercise_date: Grant of July 1, 2020 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2020. F5 · derivative.expiration_date: Grant of July 1, 2020 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2020. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 5,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000096 · edgar.xml · derivative · entry 9 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,333 Underlying: Common Stock · 5,333 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: Grant of July 1, 2020 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2020. F4 · derivative.expiration_date: Grant of July 1, 2020 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2020. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 1,778 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000096 · edgar.xml · derivative · entry 6 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,332 Underlying: Common Stock · 1,778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 666 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000096 · edgar.xml · derivative · entry 5 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: These Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,778 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000096 · edgar.xml · nonDerivative · entry 2 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:30 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 666 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-20-000096 · edgar.xml · nonDerivative · entry 1 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 01:47 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $26.66 | $0.00 |
DisclosureSEC source: 0000874015-20-000084 · primary_doc.xml · derivative · entry 3 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 10,000 shares Expires 2023-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 01:47 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 10,000 | $60.00 | $600,000.00 |
DisclosureSEC source: 0000874015-20-000084 · primary_doc.xml · nonDerivative · entry 2 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,183 F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on March 5, 2020. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 01:47 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 10,000 | $26.66 | $266,600.00 |
DisclosureSEC source: 0000874015-20-000084 · primary_doc.xml · nonDerivative · entry 1 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on March 5, 2020. Read SEC document |
| July 03, 2019 Filed Jul 3, 2019 23:02 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 667 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-19-000112 · edgar.xml · derivative · entry 8 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,333 Underlying: Common Stock · 667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 03, 2019 Filed Jul 3, 2019 23:02 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 667 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-19-000112 · edgar.xml · nonDerivative · entry 4 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 23:02 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 889 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-19-000112 · edgar.xml · derivative · entry 7 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,666 Underlying: Common Stock · 889 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 23:02 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 889 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-19-000112 · edgar.xml · nonDerivative · entry 3 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 23:02 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantDirector Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $64.80 | $0.00 |
DisclosureSEC source: 0000874015-19-000112 · edgar.xml · derivative · entry 10 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2029-06-30 F5 · derivative.exercise_date: Grant of July 1, 2019 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 1, 2020. The option shall be fully vested and exercisable on July 1, 2023. The option is exercisable to 0 shares on July 1, 2019. F5 · derivative.expiration_date: Grant of July 1, 2019 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 1, 2020. The option shall be fully vested and exercisable on July 1, 2023. The option is exercisable to 0 shares on July 1, 2019. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 23:02 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 7,110 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-19-000112 · edgar.xml · derivative · entry 9 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,110 Underlying: Common Stock · 7,110 shares Expires not disclosed F1 · derivative.exercise_price: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F4 · derivative.exercise_date: Grant of July 1, 2019 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 1, 2020. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 1, 2023. The RSU is vested as to 0 shares on July 1, 2019. F4 · derivative.expiration_date: Grant of July 1, 2019 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 1, 2020. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 1, 2023. The RSU is vested as to 0 shares on July 1, 2019. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 23:02 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 667 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-19-000112 · edgar.xml · derivative · entry 6 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666 Underlying: Common Stock · 667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 23:02 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 666 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-19-000112 · edgar.xml · derivative · entry 5 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 23:02 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 667 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-19-000112 · edgar.xml · nonDerivative · entry 2 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 23:02 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 666 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-19-000112 · edgar.xml · nonDerivative · entry 1 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| July 03, 2018 Filed Jul 3, 2018 19:13 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 667 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000083 · edgar.xml · derivative · entry 4 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 03, 2018 Filed Jul 3, 2018 19:13 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 667 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000083 · edgar.xml · nonDerivative · entry 2 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 19:13 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantDirector Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $42.88 | $0.00 |
DisclosureSEC source: 0000874015-18-000083 · edgar.xml · derivative · entry 6 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-07-01 F5 · derivative.exercise_date: Grant of July 2, 2018 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 2, 2019. The option shall be fully vested and exercisable on July 2, 2022. The option is exercisable to 0 shares on July 2, 2018. F5 · derivative.expiration_date: Grant of July 2, 2018 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 2, 2019. The option shall be fully vested and exercisable on July 2, 2022. The option is exercisable to 0 shares on July 2, 2018. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 19:13 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 3,555 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000083 · edgar.xml · derivative · entry 5 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,555 Underlying: Common Stock · 3,555 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: Grant of July 2, 2018 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 2, 2019. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 2, 2022. The RSU is vested as to 0 shares on July 2, 2018. F4 · derivative.expiration_date: Grant of July 2, 2018 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 2, 2019. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 2, 2022. The RSU is vested as to 0 shares on July 2, 2018. Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 19:13 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000083 · edgar.xml · derivative · entry 3 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,999 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 19:13 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000083 · edgar.xml · nonDerivative · entry 1 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| July 03, 2017 Filed Jul 3, 2017 21:31 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantDirector Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $52.22 | $0.00 |
DisclosureSEC source: 0000874015-17-000037 · edgar.xml · derivative · entry 4 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2027-07-02 F5 · derivative.exercise_date: Grant of July 3, 2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 3, 2018. The option shall be fully vested and exercisable on July 3, 2021. The stock option was exercisable as to 0 shares on July 3, 2017. F5 · derivative.expiration_date: Grant of July 3, 2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 3, 2018. The option shall be fully vested and exercisable on July 3, 2021. The stock option was exercisable as to 0 shares on July 3, 2017. Read SEC document |
| July 03, 2017 Filed Jul 3, 2017 21:31 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 2,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000037 · edgar.xml · derivative · entry 3 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,667 Underlying: Common Stock · 2,667 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: Grant of July 3, 2017 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 3, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 3, 2021. The RSU is vested as to 0 shares on July 3, 2017. F4 · derivative.expiration_date: Grant of July 3, 2017 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 3, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 3, 2021. The RSU is vested as to 0 shares on July 3, 2017. Read SEC document |
| July 01, 2017 Filed Jul 3, 2017 21:31 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 3,406 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000037 · edgar.xml · derivative · entry 2 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,999 Underlying: Common Stock · 3,406 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 01, 2017 Filed Jul 3, 2017 21:31 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 3,406 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000037 · edgar.xml · nonDerivative · entry 1 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 10:41 UTC | USMD Holdings, Inc. USMD · Entity 181842 | Disposition to issuerCommon Stock ($.01 par value) | 14,491 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-16-030646 · doc4.xml · nonDerivative · entry 1 Castleman Breaux · CIK 0001335073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of at the effective time of the merger of Project Z Merger Sub, Inc. ("Merger Sub"), a wholly-owned subsidiary of WellMed Medical Management, Inc., a Texas corporation ("WellMed"), with and into the issuer (the "Merger"), pursuant to that certain Agreement and Plan of Merger dated August 29, 2016, between the issuer, WellMed and Merger Sub, in exchange for a cash payment of $22.34 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.